


claims of Groups I and II is improper since the pharmaceutical compositions within the scope of Group I may or may not include a signalling system. Note that original claim 1 does not require a signalling system but that dependent claim 25 does require the signalling system. Similarly the claims of Group II may or may not require a signalling system. Note that claim 30 does not require a signalling system, but that claim 31 does require the signalling system. Therefore there is no correspondence between the claims of Groups I and II and whether the claimed composition or claimed method of administering the claimed composition includes a signalling system within the composition. The claims of Group I include compositions both with and without a signalling system and the method of administration claims of Group II include the administration of compositions both with and without signalling systems. Thus whether the compositions include a signalling system is not a basis on which the Examiner can properly require restriction.

An action on the merits is awaited.

Respectfully submitted,  
The Firm of Karl F. Ross P.C.



Jonathan Myers, Reg. No. 26,963  
Attorney for Applicant

er  
10 June 2002  
5676 Riverdale Avenue Box 900  
Bronx, NY 10471-0900  
Cust. No.: 535  
Tel: (718) 884-6600  
Fax: (718) 601-1099